Watch ACBM. Know when insiders buy.
One email the day a filing lands. Free.
ACBM
ACRO BIOMEDICAL CO., LTD.
0.03
+0.00 +0.00%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.6MP/E —DIV YIELD —FCF YIELD —REV TTM $0NET INCOME −$140KNET CASH —52W 0.00 – 0.03SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$18K | −$21K | — | 0.00 | −$11K | — | — | Aug 14 |
| Q1 2026 · Mar 31 | $0 | — | — | −$60K | −$44K | — | 0.00 | −$50K | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$16K | $43K | — | 0.00 | −$25K | — | — | Feb 11 |
| Q3 2025 · Sep 30 | $0 | — | — | −$115K | −$118K | — | 0.00 | −$54K | — | — | Nov 10 |
| Q2 2025 · Jun 30 | $0 | — | — | −$14K | −$16K | — | 0.00 | −$94K | — | — | Aug 14 |
| Q1 2025 · Mar 31 | $0 | — | — | −$9K | −$10K | — | 0.00 | −$23K | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$9K | −$11K | — | 0.00 | −$11K | — | — | Feb 11 |
| Q3 2024 · Sep 30 | $0 | — | — | −$9K | −$10K | — | 0.00 | −$6K | — | — | Nov 10 |
| Q2 2024 · Jun 30 | $0 | — | — | −$9K | −$10K | — | 0.00 | −$6K | — | — | Nov 10 |
| Q1 2024 · Mar 31 | $0 | — | — | −$10K | −$11K | — | 0.00 | −$14K | — | — | Nov 10 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$17K | −$18K | — | 0.00 | −$13K | — | — | Jul 24 |
| Q3 2023 · Sep 30 | $0 | — | — | −$1.6M | −$1.6M | — | -0.03 | $483 | — | — | Jul 23 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$154K | −$101K | — | 0.00 | −$196K | — | — | — | — |
| FY2024 · to Dec 31 | $0 | — | −$38K | −$42K | — | 0.00 | −$37K | — | — | — | — |
| FY2023 · to Dec 31 | $0 | — | −$8.8M | −$8.8M | — | -0.15 | −$15K | — | — | — | — |
| FY2022 · to Dec 31 | $659K | 21.3% | −$15.9M | −$15.9M | -2410.2% | -0.26 | −$147K | — | — | — | — |
| FY2021 · to Dec 31 | $1.2M | 21.7% | −$7.7M | −$7.7M | -642.8% | -0.14 | $299K | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$130K | −$117K | — | 0.00 | −$199K | — | — | — | — |
Every number comes from ACRO BIOMEDICAL CO., LTD.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.